Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth formulary coverage & prior auth updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    EmblemHealth Large Group ASO NRA Preferred Formulary (2026)

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists covered prescription drugs, formulary tiers, and common plan restrictions (e.g., prior authorization, quantity limits, step therapy, specialty pharmacy) for EmblemHealth Large Group ASO NRA Preferred members as of Jan. 1, 2026 and informs members and providers how to use the formulary.

    Policy Summary
    PayerEmblemHealth
    PolicyEmblemHealth Large Group ASO NRA Preferred Formulary (2026)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is annotated 'PA' before dispensing to prevent denial of coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-01-01formulary effective/updated date
    multiple PA/QL/LA/SPutilization controls present
    Language assistancemultilingual support available
    ~150drug line-items in excerpt
    PA/LA/SP/ACAflags present

    Coverage Criteria and Formulary Rules

    General coverage rules

    Formulary coverage is determined by tier placement and any associated utilization management indicators; coverage may require meeting listed utilization controls before the plan will pay.

    Formulary listing and tier: Drug must be listed in the formulary and assigned to a Drug Tier (ACA/Tier 1/Tier 2/Tier 3) to be considered for coverage.

    See formulary line-item for assigned tier and benefit implications.

    Utilization management flags: When a formulary line-item includes one or more Requirements/Limits flags (PA, QL, LA, SP, ST), the corresponding requirement must be satisfied for plan payment.PA/QL/LA/SP/ST

    Examples and definitions of these flags are shown on the formulary (see abbreviations).

    Prior authorization consequence: If a drug is annotated 'PA' a prior authorization must be obtained before dispensing; failure to obtain PA may result in non‑coverage.
    Policy Summary
    PayerEmblemHealth
    PolicyEmblemHealth Large Group ASO NRA Preferred Formulary (2026)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is annotated 'PA' before dispensing to prevent denial of coverage.
    SourceLink
    On This Page
    Coverage Criteria and Formulary RulesFormulary Line Items and Coding ExamplesProvider Actions, Prior Authorization, and DocumentationFormulary Background and ScopeDefinitions and Utilization FlagsInitial Therapy CriteriaStep Therapy Rules and SequencesQuantity Limits (Per Product Examples)Site of Care and Specialty RoutingBiosimilars and Related Controls
    PA

    Prior authorization process and required documentation are per payer procedures.

    Quantity limits consequence: When a Quantity Limit (QL) is listed, dispensing must be within the stated units/time period or the claim may be denied or limited.QL

    Quantity limits are shown on each line (e.g., tablets/30 days, mLs/30 days, packets/28 days).

    Specialty and limited access handling: Products labeled 'SP' (specialty) or 'LA' (limited access) may require specialty pharmacy routing or restricted distribution per the formulary entry.SP/LA

    Site-of-care or channel requirements appear on the product line; follow payer routing instructions.

    Covered drugs (with possible utilization controls)

    Formulary listing indicates in‑formulary coverage status; many entries include Requirements/Limits specifying utilization management (PA, QL, LA, SP).

    Listed drug coverage: Drugs shown by therapeutic class with assigned Drug Tier are considered covered subject to plan benefits and any Requirements/Limits noted on the line item.

    Coverage remains subject to the member's Certificate of Coverage and payer policies.

    Utilization controls may apply: Requirements/Limits fields on line-items may include PA (prior authorization), QL (quantity limits), LA (limited access), SP (specialty), and/or ST (step therapy); each control must be met for payment.PA/QL/LA/SP/ST

    See individual formulary entries for exact flags and limits (examples in antiviral and specialty sections).

    Selected antiviral/hepatitis coverage rules

    Coverage and dispensing are subject to drug‑specific requirements as noted on each formulary line (examples shown below).

    Hepatitis C and selected antivirals: Direct‑acting antivirals and selected high‑cost antiviral/antiretroviral agents (e.g., MAVYRET, SOVALDI, VOSEVI) are listed with PA and QL; coverage requires a prior authorization and dispensing within the stated quantity limits.PA + QL

    See each antiviral line for pack/tablet counts and any SP/LA designations (e.g., MAVYRET QL 84 tablets/28 days; VOSEVI QL 28 tablets/28 days).

    Other antiviral controls: Some antiviral agents (e.g., SUNLENCA/lenacapavir, PAXLOVID pack sizes) have specific QL or LA/SP annotations; follow the Requirements/Limits for authorization and quantity rules.QL/LA/SP

    Examples include QL entries and LA/SP flags on individual antiviral line-items.

    Vaccine coverage indicators

    Vaccines listed include an ACA flag when preventive/mandated coverage applies.

    ACA‑flagged vaccines: Vaccines annotated 'Requirements/Limits = ACA' (for example, ABRYSVO, ACTHIB, FLU vaccines, JYNNEOS, M‑M‑R II, meningococcal vaccines) indicate coverage consistent with Affordable Care Act preventive vaccine requirements.ACA

    Refer to the vaccine formulary line for tier and any administration or site‑of‑care details.

    Non‑ACA vaccines: Vaccines without the ACA flag are listed with Drug Tier and may still have other Requirements/Limits; follow the line item for QL or other instructions.

    Administration and coverage depend on plan benefit and vaccine indication.

    Formulary coverage with utilization controls

    Coverage and utilization controls apply as listed for each product; items flagged with PA/LA/SP require prior authorization and/or specialty handling.

    Formulary entries with controls: Each listed drug includes an assigned Drug Tier and, where present, Requirements/Limits such as QL (quantity limits), PA (prior authorization), LA (limited access), SP (specialty), and ST (step therapy). These controls must be met for coverage and claim payment.PA/QL/LA/SP/ST

    Examples: inhaler QL (e.g., fluticasone‑salmeterol QL 1 inhaler/30 days), specialty biologics with PA/QL/SP (e.g., TREMFYA PA + QL 1 syringe/28 days), and LA/PA/QL on select GI specialty agents (e.g., BYLVAY).

    Provider documentation and site‑of‑care: When PA, LA, or SP appear on a product line, prescribers and dispensing pharmacies must follow payer prior authorization and documentation processes and route through the indicated specialty or limited‑access channel.PA/LA/SP

    Failure to obtain required authorization or to follow site‑of‑care routing may result in denial of coverage.

    Not all drugs shown in this formulary are payable under every drug benefit. Coverage for any given medication is subject to the member’s specific plan terms as described in the member’s Certificate of Coverage. Members and providers should confirm benefit eligibility, copay/coinsurance, and any plan-specific requirements (for example, prior authorization or quantity limits) before assuming coverage.

    The excerpt provided does not include a separate list of drugs that are explicitly excluded from coverage. Where exclusions or special limitations apply, those details are maintained in plan documents and member materials rather than in this excerpt.

    Within the supplied document segments there are no explicit exclusion entries shown. The listings present covered products with associated tiers and utilization controls (e.g., PA, QL, SP) but do not enumerate specific exclusions in these chunks.

    This segment does not provide explicit exclusion conditions. PALFORZIA and similar products are shown with program indicators (e.g., LA, SP) and ACA flags, but no exclusion rules are stated in these chunks.

    No explicit coverage exclusion statements are present in these excerpts; entries primarily identify drug tiers and utilization management flags such as PA, QL, LA, and SP rather than listing excluded products.

    The provided excerpt does not state explicit exclusions. Drug lines in these chunks list requirements/limits (for example, PA and QL) and specialty designations but do not declare specific excluded items.

    There are no explicit 'not medically necessary' (NMN) determinations presented in the supplied chunks. Clinical coverage decisions that designate services or drugs as NMN would be addressed in plan medical policy or benefit documentation beyond this excerpt.

    No statements labeling products as Not Medically Necessary (NMN) appear in the available chunks. The listings instead emphasize formulary placement and utilization controls (e.g., QL, PA).

    This excerpt does not include 'not medically necessary' policy language. Entries shown specify prior authorization, quantity limits, and specialty flags but do not contain NMN determinations in these sections.

    Formulary Line Items and Coding Examples

    Contraceptives and Hormonal Therapies - covered/ACAmixedCovered
    ANNOVERAsegesterone acetate-ethinyl estradiol vaginal ring 0.15-0.013 mg/24hr — Requirements/Limits = ACA
    ARANELLEnorethindrone-ethinyl estradiol tablets (various strengths) — Requirements/Limits = ACA
    BEYAZdrospirenone-ethinyl estradiol-levomefolate tab 3-0.02-0.451 mg — Requirements/Limits = ACA
    DEPO-PROVERA CONTRACEPTIVmedroxyprogesterone acetate IM suspension 150 mg/ml — Requirements/Limits = ACA
    DEPO-SUBQ PROVERA 104medroxyprogesterone acetate subq suspension pref syringe 104 mg/0.65ml — Requirements/Limits = ACA
    desogestrel-ethinyl estradiolcombined oral contraceptive tab 0.15-0.02/0.01 mg (21/5) — Requirements/Limits = ACA
    desogestrel & ethinyl estradiolcombined oral contraceptive formulations — Requirements/Limits = ACA
    Formulary utilization flags — neutralmixed
    PAPrior Authorization indicated
    QLQuantity Limit applies (values vary by product)
    SPSpecialty distribution or handling
    LALimited/limited access or limited availability
    ACAAffordable Care Act preventive or mandated coverage
    Formulary drug/vaccine line-items — neutralmixed
    FLUZONE 2025-2026influenza virus vaccine split im susp pref syringe 0.5 ml — Requirements/Limits = ACA
    GARDASIL 9hpv 9-valent recombinant vaccine — Requirements/Limits = ACA
    HEPLISAV-Bhepatitis B vaccine recomb adjuvanted pref syr 20 mcg/0.5ml — Requirements/Limits = ACA
    M-M-R IImeasles-mumps-rubella vaccine for injection — Requirements/Limits = ACA
    VAXNEUVANCEpneumococcal 15-valent conjugate vaccine pref syr 0.5 ml — Requirements/Limits = ACA
    VARIVAXvaricella vaccine live for injection 1350 pfu/0.5ml — Requirements/Limits = ACA
    JYNNEOSsmallpox & monkeypox vaccine, live non-replicating inj 0.5 ml — Requirements/Limits = ACA
    IPOL INACTIVATED IPVpoliovirus vaccine injection — Requirements/Limits = ACA
    VAXCHORAcholera vaccine live attenuated oral suspension — Requirements/Limits = ACA
    Sample drug entries from excerpt — neutralmixed
    AMOXICILLINmultiple strengths and formulations listed (capsules, tablets, suspensions) — tiers 1-3
    ARIKAYCEamikacin sulfate liposome inhalation suspension 590 mg/8.4 ml — Requirements: LA, PA, QL (28 vials/28 days), SP
    APRETUDEcabotegravir IM extended release suspension 600 mg/3 ml — Requirements: ACA, LA, SP
    BARACLUDEentecavir oral solution 0.05 mg/ml — tier 2
    BIKTARVYbictegravir-emtricitabine-tenofovir AF combination tablets — tier 2
    LIVTENCITYmaribavir tab 200 mg — Requirements: LA, QL, SP
    VOSEVIsofosbuvir-velpatasvir-voxilaprevir tab 400-100-100 mg — PA, QL, SP
    Additional drug entries — neutralmixed
    KISQALIribociclib succinate tab packs — PA, QL, SP
    KRAZATIadagrasib tab 200 mg — LA, PA, QL, SP
    LENVIMAlenvatinib capsule therapy packs — LA, PA, QL, SP
    Listed drug formulations — neutralmixed
    AMOXICILLIN (various)chew tabs 125/250 mg; caps 250/500 mg; suspensions 125/5ml–400/5ml; tabs 500 mg, 875 mg
    AZITHROMYCINsuspension and tablet formulations (not fully excerpted)
    ACYCLOVIRcaps 200 mg, susp 200 mg/5ml, tabs 400/800 mg
    LAMIVUDINEoral solution 10 mg/ml; tabs 100/150/300 mg
    MAVYRETtablets and pellet packs — PA, QL, SP
    ISENTRESSraltegravir tabs 400/600 mg — QL limits noted
    VOSEVISOF/VEL/VOX 400/100/100 mg — PA, QL, SP
    ANNOVERAsegesterone-ethinyl estradiol vaginal ring — ACA
    DEPO-PROVERAmedroxyprogesterone acetate IM susp 150 mg/ml — ACA
    REBIF TITRATION PACKinterferon beta-1a prefilled syringe kit — PA, QL (1 kit/180 days), SP
    Specialty and select oral agents — neutralmixed
    SOMAVERTpegvisomant injection — LA, SP
    SKYTROFAlonapegsomatropin cartridges — LA, PA, SP
    STRENSIQasfotase alfa injection — LA, PA, SP
    TRYNGOLZAolezarsen subcut auto-inject — LA, PA, QL, SP
    TYMLOSabaloparatide pen-injector — LA, PA, QL, SP
    Specialty injectables — neutralmixed
    ADALIMUMAB biosimilarsmultiple prefilled syringe and auto-injector presentations — PA, QL, SP
    ENBRELetanercept prefilled syringe/cartridge/auto-injector — PA, QL, SP
    ORENCIAabatacept subcutaneous prefilled syringe/auto-injector — PA, QL, SP
    SKYRIZIrisankizumab cartridges/pref syringes — PA, QL, SP
    Cardiovascular agents — neutralmixed
    DIGOXINoral solution 0.05 mg/ml and tablets 62.5/125/250 mcg — Requirements/Limits = PA for some presentations
    ISOSORBIDE MONONITRATEtablets and ER formulations — various tiers
    NITROGLYCERINsublingual tablets, transdermal patches, ointments — multiple tiers and limits
    BETA BLOCKERSatenolol, metoprolol, carvedilol, propranolol (including HEMANGEOL) — various presentations and QL/LA notes
    Antiarrhythmics & Antihypertensives — neutralmixed
    FLECAINIDEcap 50/100/150 mg — listed
    MEXILETINEcapsules 150/200/250 mg — listed
    MULTAQdronedarone 400 mg tab — listed
    Antidepressants — neutralmixed
    BUPROPIONimmediate and extended-release formulations — QL limits noted
    CITALOPRAMoral solution and tablets — QL limits noted
    DULOXETINEenteric coated pellets caps 20/30/60 mg — QL limits
    EMSAMselegiline TD patch 6/9/12 mg/24hr — listed
    Selected newer agents / antipsychotics — neutralmixed
    CAPLYTAlumateperone caps — QL noted
    REXULTIbrexpiprazole tabs — QL noted
    VRAYLARcariprazine caps — QL noted
    Hypnotics / ADHD products — neutralmixed
    BELSOMRAsuvorexant 5/10/15/20 mg — QL, ST
    ESZOPICLONELunesta 1/2/3 mg — QL limits
    AMPHETAMINESamphetamine-dextroamphetamine ER/IR formulations — QL limits for controlled medications
    ADHD NONSTIMULANTSatomoxetine, guanfacine ER — QL limits
    Sample listed drugs and limits — neutralmixed
    REBIF TITRATION PACKinterferon beta-1a pref syr kit — PA, QL (1 kit/180 days), SP
    SODIUM OXYBATEsodium oxybate oral solution 500 mg/ml — LA, PA, QL (3 bottles/30 days), SP
    SODIUM PHENYLBUTYRATEglycerol phenylbutyrate liquid 1.1 gm/ml RAVICTI — LA, PA, SP
    XYWAVcalcium/mag/potassium/sodium oxybates oral solution 500 mg/ml — LA, PA, QL (540 mls/30 days), SP
    VYLEESIbremelanotide subcutaneous auto-inject — LA, PA, QL (6 pens/30 days), SP
    WAINUAeplontersen sodium subcut auto-inj 45 mg — LA, PA, QL (1 pen/30 days), SP
    Additional specialty drugs — neutralmixed
    ZEPOSIAozanimod capsules and starter kits — PA, QL, SP
    TYK2/biologicsvarious biologic therapies listed with PA/QL requirements
    PIQRAY / POMALYST / ROZLYTREKoncology QL/PA examples — PIQRAY (PA, QL), POMALYST (LA, PA, QL), ROZLYTREK (LA, PA, QL)
    Analgesics - selected entries — neutralmixed
    ASPIRINvarious formulations including low-dose and delayed release — ACA noted for preventive uses
    BUTALBITAL combinationsbutalbital-acetaminophen +/- caffeine +/- codeine — QL limits
    BELBUCAbuprenorphine buccal film — PA, QL
    Opioids and controlled analgesics — neutralmixed
    FENTANYL patchesTD patches 12-100 mcg/hr — PA, QL (15 patches/30 days)
    MORPHINE SULFATEmultiple ER and IR formulations — PA and QL for certain ER products
    OXYCODONEconcentrates, solutions, and tablets — QL limits specified
    METHADONEsolutions and tabs for opioid use disorder/pain — QL limits
    TRAMADOLimmediate and ER formulations — PA/QL for ER versions
    Biologics and advanced therapies — neutralmixed
    ADALIMUMAB seriesmultiple biosimilars and presentations — PA, QL, SP
    ETANERCEPT (ENBREL)prefilled syringes/cartridges/auto-injectors — PA, QL, SP
    RISANKIZUMAB (SKYRIZI)cartridges/prefilled syringes — PA, QL, SP
    GUSELKUMAB (TREMFYA)prefilled syringe — PA/QL noted
    UPADACITINIB (RINVOQ)ER tabs 15/30 mg — LA, PA, QL
    Quantity limits — summary
    Quantity limits examples (summary)
    Example quantity limits
    Example QL — MAVYRET and SOVALDI examples
    Assorted QL examples
    Quantity limits examples — assorted tablet/capsule examples
    Oncology and specialty QL examples
    Quantity limits — oncology and specialty QL examples (PIQRAY, POMALYST, ROZLYTREK)
    Vials/pens QL examples
    Quantity limits examples — vials/pens examples
    Oral solution QL examples
    Oral solution QL examples
    Renal / GI QL examples
    Quantity limits examples (renal / GI agents)
    XYWAV quantity limit example
    XYWAV quantity limit example
    REBIF TITRATION PACK quantity limit
    REBIF TITRATION PACK quantity limit
    Adalimumab biosimilars QL examples
    Adalimumab biosimilars QL examples

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Many drugs listed in this formulary require prior authorization (PA) before the plan will cover them. Prior authorization may be required for specific high-cost antiviral and hepatitis therapies (for example, EPCLUSA, MAVYRET, MAVYRET pellet packs, VOSEVI, VOSEVI pellet packs, SOVALDI-type regimens) as well as select antifungals. Numerous specialty and limited-access products (marked SP and/or LA) — including many oncology, biologic, gene, and enzyme therapies — also require PA and often have quantity limits (QL) or site-of-care restrictions. Failure to obtain required PA or to adhere to QL/LA/SP requirements may result in claim denial or delay.

    • Prior Authorization Required: Drugs annotated 'PA' require approval before dispensing; without approval the plan may not cover the drug.
    • High-cost antivirals/hepatitis agents: Examples listed with PA and often QL/SP include EPCLUSA (sofosbuvir-velpatasvir) and MAVYRET (glecaprevir-pibrentasvir) — PA is required for tablets and pellet/packet formulations.
    • Selected antifungals: Certain agents (e.g., CRESEMBA/isavuconazonium) are marked PA and require authorization prior to coverage.
    • Selected specialty drugs: Many specialty therapies across therapeutic classes (oncology agents, enzyme therapies, biologics, gene therapies) are marked LA, PA, SP and require prior authorization and may have quantity limits.
    • PA for specific antiviral/hepatitis therapies: Products such as EPCLUSA, MAVYRET, VOSEVI, MAVYRET pellet packs and VOSEVI pellet packs are subject to PA, QL, and SP designations.
    • PA required for many specialty drugs: Examples include numerous antineoplastics and supportive oncology agents (abiraterone/Zytiga, alpelisib/PIQRAY, selinexor/XPOVIO, many targeted oral agents) and immunomodulators — these are frequently LA, PA, QL, SP.
    • Products requiring PA/QL: Several products list both PA and specified quantity limits (e.g., EPCLUSA QL 28 tablets/28 days; MAVYRET QL 84 tablets/28 days; many oncology and specialty agents list numeric QLs).
    • Prior Authorization required for listed LA/PA/SP drugs: Items flagged LA/PA/SP (for example, ARIKAYCE, TOBI PODHALER, many biologics and enzyme replacements) require PA and may be limited to certain pharmacies or channels.
    • Prior Authorization required for select specialty and high-cost agents: Examples include CHOLBAM, BYLVAY-type agents, ENTYVIO PEN, maralixibat/LIVMARLI, and other high-cost orphan or specialty drugs marked LA/PA/SP.
    • PA/SP/LA required for specific products: Many products annotated with any combination of PA, SP, LA require submission of authorization per the plan's prior authorization process (examples throughout the formulary).
    • Prior authorization may trigger denial: Claims submitted without required PA, or exceeding QL, or not meeting LA/SP conditions, may be denied until authorization/documentation is provided.
    • High-cost antiviral requirements: Antiviral/hepatitis regimens (sofosbuvir-based regimens, glecaprevir-pibrentasvir, voxilaprevir combinations) carry PA and SP designations and often QLs; prior approval is expected before dispensing.
    • PA/QL/SP requirements for listed specialty drugs: Specialty products commonly require PA plus QL and are often restricted to specialty pharmacies or limited distribution networks (LA).
    • PA/LA/SP trigger: Any item labeled PA, LA or SP in the formulary should be treated as requiring prior approval and may have additional site-of-care or dispensing channel requirements.
    • PA/LA may trigger denial: Failure to meet PA or LA conditions (for example dispensing outside permitted pharmacies) can lead to claim denial.
    • Quantity limit exceedance: Requests exceeding the listed QL (for example XYWAV QL 540 mL/30 days, EPCLUSA QL 28 tablets/28 days) may be denied unless an exception is authorized.
    • Authorization risk for flagged products: Coverage is subject to utilization management controls (PA, ST, SP, LA, QL) — providers should verify requirements before prescribing or dispensing.
    Documentation Required

    Provider Documentation and Submission Requirements

    When a drug is flagged PA, prescribers must follow the payer's prior authorization process and provide supporting clinical documentation. For LA and SP products, additional documentation (site-of-care justification, distribution channel adherence, specialty pharmacy enrollment) is often required. Documentation should justify medical necessity, prior trials (when step therapy/ST applies), dosing, duration, and reason for any requested QL exceedance. The plan may request PA forms, clinical notes, laboratory results, or prior treatment history to support approval.

    • Documentation expectations: Provide clinical rationale, prior treatment history, relevant labs, and any required PA forms to support the PA request.
    • Specialty / limited access documentation: For LA/SP products (for example many biologics, enzyme therapies, and orphan drugs), include site-of-care justification and ensure dispensing through approved channels/specialty pharmacies when required.
    • PA and QL documentation expected: For drugs with both PA and QL, include dosing schedule and justification for the quantity requested relative to the listed QL (examples: OZEMPIC 1 pen/28 days, EPCLUSA 28 tablets/28 days).
    • Documentation for PA: Prescribers must supply clinical evidence and any required forms per the plan's PA procedures; incomplete documentation may delay or result in denial.
    • Documentation for PA/QL/LA/SP: Follow the payer's prior authorization process for products marked with these flags; documentation must address all applicable controls.
    • Documentation for PA/LA agents: For drugs that are both PA and LA, include information proving appropriateness of limited distribution channel or specialty pharmacy enrollment.
    Step Therapy

    Step Therapy

    Step therapy (ST) applies to some products. Where ST is indicated, the plan requires trials of specified first-line agents before covering the requested therapy. Not all step therapy details are listed in this excerpt; providers should consult the plan's PA criteria or clinical policy for exact step requirements and allowable exceptions.

    • Step therapy requirement: Drugs annotated 'ST' require documented trials of preferred alternatives before the requested agent will be approved.
    • Step therapy present for select products: Certain CNS and psychiatric medications, and other classes (examples in the formulary: FETZIMA noted with ST; select antidepressants and antipsychotics have ST annotations).
    • Step therapy is not explicitly detailed here: Refer to the payer's clinical prior authorization criteria for specifics on acceptable first-line therapies, trial duration, and documentation required.
    Prior Authorization

    Product-Level and Pack-Specific Authorization (e.g., Palforzia)

    Some products have multiple levels or kit/pack variants (for example Palforzia starter/level/maintenance packs) that are designated LA and SP and require adherence to the specific product level when requesting authorization. Ensure PA requests reference the exact product level or pack to avoid processing delays.

    • Palforzia — product levels listed: Starter, Level 0, Level 1, Level 10, Level 11 (maintenance/titration) are marked LA and SP and require appropriate authorization for the specific level/pack.
    • LA/SP implications: Limited availability and specialty designations may impose site-of-care, dispensing pharmacy, or monitoring requirements; include level/pack detail in PA documentation.

    Formulary Background and Scope

    This formulary organizes medications into defined tiers (for example, ACA/preventive, Tier 1–3) to indicate in‑formulary placement and to guide member cost sharing. Each drug line also shows any applicable utilization management indicators—such as PA (prior authorization), QL (quantity limit), LA (limited access), or SP (specialty)—that must be satisfied for plan payment. Refer to individual formulary entries for exact requirements and the member’s Certificate of Coverage for benefit details.

    Definitions and Utilization Flags

    PA definition — Prior Authorization requires approval before covering the drug
    PA (Prior Authorization)The plan requires approval before you fill your prescription; failure to obtain approval may result in non‑coverage.
    QL (Quantity Limit)The plan limits the amount of the drug it will cover (specified as units per time period).
    SP (Specialty)Specialty drugs may require special handling, monitoring, and education and are often routed via specialty pharmacy.
    QL definition — Quantity Limit explanation
    Quantity Limit (QL)The plan limits the amount of the drug it will cover; typically shown as maximum units per specified time period (e.g., 60 tablets/30 days).
    Examples shownQL values appear as tablets/30 days, packets/28 days, mLs/30 days depending on formulation.
    Effect on claimsRequests exceeding stated QL may be denied unless authorized per payer process.
    SP definition — Specialty Drugs requiring special handling
    SP (Specialty Drug)Specialty drugs may require special handling, monitoring, and unique education and are often managed via specialty pharmacy channels.
    ImplicationsSP designation often accompanies PA and QL and may indicate restricted distribution (LA) or site-of-care controls.
    ExamplesMany biologics, enzyme therapies and high-cost injectables are flagged SP in the formulary.
    ST definition — Step Therapy explanation
    ST (Step Therapy)Requires trying specified first-line drugs before the plan will cover alternatives; documented failure of the first-line agent permits coverage of the alternative.
    Where usedSome agents in the formulary are flagged 'ST' indicating step therapy requirements may apply (e.g., select CNS/psychiatric agents).
    Provider actionPrescribers must document prior trials or failure per payer step therapy requirements when ST is indicated.
    PA / QL / LA / SP — utilization flag summary
    Utilization flags summarizedPA = Prior Authorization; QL = Quantity Limit; LA = Limited Access; SP = Specialty — flags indicate utilization management controls on formulary lines.
    Claims impactEntries flagged with PA/QL/LA/SP may require prior approval, specialty routing, or adherence to QL or may be denied if requirements unmet.
    Provider responsibilitiesFollow payer prior authorization and documentation processes when these flags appear on a drug line.
    QL detailed note — maximum units per time period
    Maximum units per periodQuantity Limits are expressed as maximum units (tablets, capsules, mLs, pens, kits) per specified time period (e.g., 60 tablets/30 days).
    Formulation-specific unitsLiquid products use mLs, inhalers use counts (e.g., 1 inhaler/30 days), injectables/pens use pens or syringes per period.
    Denial riskClaims exceeding the stated QL risk denial without prior authorization or exception documentation.
    PA short definition
    PA (short)Prior Authorization — plan approval required before coverage.
    When shownIndicated in Requirements/Limits column for specific drugs requiring pre-approval.
    ConsequenceFailure to obtain PA may result in non-coverage.
    SP short definition
    SP (short)Specialty — managed via specialty pharmacy channels, often with PA and QL
    ExamplesMany biologics and high-cost injectables are SP (e.g., PREGNYL, REPATHA).
    Site implicationsMay require specialty distribution or limited access settings.
    ACA definition — preventive/mandated vaccine coverage indicator
    ACA (short)Affordable Care Act indicator — used on vaccine lines to denote preventive/mandated coverage where applicable.
    EffectVaccines marked ACA may be covered under preventive requirements; see vaccine line-items for specifics.
    ExamplesGARDASIL 9, FLUZONE and other vaccines are annotated ACA in the formulary.
    LA short definition
    LA (short)Limited Access — indicates restricted distribution or that the drug may be available only at select pharmacies or sites.
    Common usageOften applied alongside PA and SP for high-cost specialty therapies.
    ExamplesEntries such as ARIKAYCE, many specialty injectables show LA designations.
    ACA requirements/limits note
    ACA limits noteWhen 'Requirements/Limits = ACA' appears on vaccine lines, coverage or limitations follow Affordable Care Act preventive service requirements.
    Provider actionRefer to vaccine line-items for specific ACA-designated products and coverage rules.
    ExamplesFLUZONE, GARDASIL 9, HEPLISAV-B are listed with ACA annotation.
    PA/QL/SP flags summary
    PA/QL/SP flags summaryProducts marked PA, QL, LA, or SP require adherence to utilization controls (prior authorization, quantity limits, site/program routing).
    Common implicationsThese flags often appear together on oncology, biologic, and specialty drug lines.
    Provider requirementProviders must follow payer prior authorization and documentation processes when these flags are present.
    PA short definition (repeated)
    PA (repeated)Prior Authorization — approval required before coverage for drugs indicated with PA.
    Example useAppears beside many oncology and specialty agents in the formulary.
    Denial riskClaims may be denied if PA not obtained.
    QL short definition (repeated)
    QL (repeated)Quantity Limit — maximum units allowed per specified time period (e.g., 30 tablets/30 days).
    Formulation examplesTablets, capsules, mLs, pens, kits may each have QL expressed per time unit.
    EnforcementExceeding QL without authorization can lead to denial.
    LA / SP short definitions (repeated)
    LA / SP (repeated)Limited Access and Specialty — indicate restricted distribution or specialty pharmacy management; often linked with PA and QL.
    Operational impactMay require site-of-care routing or specialty dispensing per payer processes.
    ExamplesMany injectables and biologics list LA and SP together with PA/QL.
    PA/QL/LA/SP aggregated definition
    Aggregated UM definitionsPA = Prior Authorization; QL = Quantity Limit; LA = Limit of Authorization/Limited Access; SP = Specialty Pharmacy requirement.
    UsageThese abbreviations are used across formulary lines to denote required controls and routing.
    ReferenceSee each drug line in the formulary for the exact combination of flags and numeric limits.
    PA example note (DIURIL, FUROSCIX)
    PA example (DIURIL, FUROSCIX)DIURIL suspension listed with PA and QL (1200 mls/30 days); FUROSCIX listed LA, PA, QL (8 kits/180 days)
    ImplicationDemonstrates PA applied to liquid/kit formulations with specific ml or kit limits.
    Provider actionObtain PA and document clinical need for these formulations when requested.
    QL example note (mLs, syringes)
    QL examples (mLs, syringes)Liquid formulations and inhalation kits show QL in mLs or cartridge counts (e.g., QL 4800 mls/30 days in some entries; TYVASO kits 112/224 cartridges).
    ApplicationPharmacies must dispense within these unit limits unless exception authorized.
    DocumentationQuantity limit authorizations require supporting documentation per payer process.
    LA definition (payer-level restriction)
    LA definition (payer-level)Limited Access — drug availability restricted to select pharmacies or distribution channels; often paired with PA and SP.
    ImplicationMay limit point-of-sale availability; claims should follow designated site/program instructions.
    ExamplesARIKAYCE and many specialty injectables are labeled LA in the formulary.
    SP definition (specialty management)
    SP definition (specialty management)Specialty drugs require management through specialty pharmacy channels, often with PA/QL/LA controls.
    Operational noteSpecialty routing may include site-of-care, shipment, and monitoring requirements.
    ExamplesMany biologics and enzyme replacement therapies are SP-designated.
    QL definition (repeated)
    QL (repeated)Quantity Limit — maximum units allowed per time period (e.g., 60 tablets/30 days)
    EnforcementLimits are enforced per claim processing; prior authorization may be required for exceptions.
    FormatExpressed as units per days/months depending on product.
    PA definition (repeated)
    PA (repeated)Prior Authorization — approval required prior to coverage; plan may deny payment if not obtained.
    How shownAppears in Requirements/Limits column for applicable drugs.
    Provider actionSubmit PA request with required documentation as listed by the payer.
    LA definition (repeated)
    LA (repeated)Limited Access — restricted distribution or limited availability designation used by the plan.
    Operational noteMay require specialty pharmacy or particular site-of-care dispensing.
    ExampleUsed for high-cost or rare therapies in the formulary.
    SP definition (repeated)
    SP (repeated)Specialty Pharmacy requirement — drug managed through specialty channels and often requiring PA/QL.
    ExamplesUsed on many injectables, biologics, and enzyme therapies.
    ImpactMay affect dispensing site, billing, and prior authorization process.
    Prior Authorization (abbrev)
    PA (abbrev)PA
    QL (abbrev)QL
    LA (abbrev)LA
    Quantity Limit (abbrev)
    QL (abbrev)QL
    MeaningQuantity Limit
    UsageShown as units per time period on formulary lines.
    Limit of Authorization (abbrev LA)
    LA (abbrev)LA — Limit of Authorization / Limited Access
    ContextUsed to indicate restricted distribution or site/program constraints.
    Common pairingOften appears with PA and SP on specialty drug lines.
    Specialty Pharmacy requirement (abbrev SP)
    SP (abbrev)SP — Specialty Pharmacy requirement
    ImplicationRequires specialty pharmacy routing for dispensing and management.
    Associated flagsFrequently combined with PA/QL/LA on formulary entries.
    Step Therapy (abbrev ST)
    ST (abbrev)ST — Step Therapy
    MeaningMember must try specified first-line agents before coverage of alternatives is allowed.
    Where indicatedNoted on select formulary lines; follow payer step therapy process.

    Initial Therapy Criteria

    Step Therapy Rules and Sequences

    Step therapy summaryNotes
    No explicit step therapy sequences listedFormulary entries in this excerpt primarily use PA, QL, LA, and SP as utilization controls; explicit multi-step failure paths are not provided.
    Step therapy not specified for most drugs in these chunksWhere 'ST' is absent, prior authorization and quantity limits are the controlling requirements per formulary lines.
    Product / FlagStep therapy details
    Various products with PA/SP flags (e.g., MAVYRET)Some products are annotated PA and SP indicating prior authorization and specialty distribution; step requirements are not explicitly detailed in the listing.
    General noteProviders should follow PA/SP requirements where shown; the formulary does not provide explicit step sequences for these entries.
    ProductStep therapy details
    PALFORZIA (levels and packs listed)PALFORZIA entries list initial and maintenance packs and are marked LA and SP, but no explicit step-therapy sequence or step-failure criteria are provided.
    Step therapy summaryNotes
    No explicit step-therapy sequences providedExcerpt emphasizes utilization flags (PA, QL, LA, SP); step therapy sequences are not defined here.
    Drug groupStep therapy implication
    GLP-1 and specialty diabetes agents (e.g., OZEMPIC, TRULICITY)Many GLP-1 agents are annotated with PA and QL; prior authorization is required before coverage. Explicit step sequences are not listed in the excerpt.
    ProductStep therapy / flag
    KERENDIA (finerenone)Marked with QL (30 tablets/30 days) and ST — the ST flag indicates a step therapy requirement may apply; the explicit step sequence is not provided in the excerpt.
    Product categoryStep therapy implication
    Specialty and high-cost agents (multiple listings)Many specialty agents are listed with PA, LA, or SP indicating prior authorization and program controls are required prior to coverage; explicit step sequences are not shown.
    Therapeutic areaStep therapy guidance
    High-cost cardiovascular and specialty agents (e.g., REPATHA, ENTRESTO)These agents require prior authorization and have QL; formulary tier and PA may require trial of preferred agents first though no explicit step sequence is listed in the excerpt.
    Step therapy presenceNotes
    No explicit step-therapy sequences providedEntries with PA/LA suggest case-by-case review for specialty agents rather than predefined step ladders in this excerpt.
    ProductStep therapy flag
    AUVELITY (dextromethorphan-bupropion)Flagged 'ST' in the formulary indicating a step therapy requirement exists and must be followed; the specific required prior agents or failure criteria are not listed here.
    Example agents flagged STStep therapy note
    FETZIMA; TRINTELLIX; FANAPT; RISPERIDONE ODT; SECUADO; VERSACLOZThese agents are noted with 'ST' and/or QL in the listing; step therapy is required where 'ST' appears but explicit sequences/failure criteria are not provided in the excerpt.
    Product / flagsStep therapy details
    Various agents marked LA and PAPresence of LA and PA may imply step or prior authorization requirements per payer processes; explicit step sequences are not included in these chunks.

    Quantity Limits (Per Product Examples)

    HIV/hepatitis agents quantity limits examples (BIKTARVY, HARVONI, EPCLUSA, MAVYRET)
    HIV/hepatitis QLs (examples)BIKTARVY, HARVONI, EPCLUSA, MAVYRET show quantity limits such as 28–84 tablets per specified days depending on product; PA/SP often applied.
    Liquid pediatric formulationsLamivudine oral solution and emtricitabine solutions have mL-based QLs (e.g., 960 mls/30 days; 680 mls/28 days).
    Pack/packet QLsPellet packs often have packet-based QLs (e.g., 28 packets/28 days).
    Liquid formulations quantity limits (lamivudine, abacavir examples)
    Lamivudine oral solution exampleQL: 960 mls/30 days (Epivir oral soln) — pediatric/liquid formulation example
    Emtriva oral solutionQL: 680 mls/28 days listed for emtricitabine soln in formulary excerpts
    Large-volume QLsSome antiviral liquids list QLs in the thousands of mLs per month (e.g., 1840 mls for maraviroc oral soln).
    ISENTRESS 400 mg QL example
    ISENTRESS 400 mgQL: 60 tablets/30 days (ISENTRESS raltegravir 400 mg)
    ISENTRESS HDQL: 60 tablets/30 days for HD formulation
    ImplicationStandard 30-day tablet limits apply to integrase inhibitor formulations.
    MAVYRET QL example (84 tablets)
    MAVYRET QLQL: 84 tablets/28 days (PA and SP noted)
    Pellet pack variantMAVYRET pellet pack listed with QL: 140 packets/28 days
    AuthorizationPA required for MAVYRET per formulary lines.
    PAXLOVID pack size examples
    PAXLOVID pack sizesQL examples: pack-based QLs listed (e.g., QL 11–20 tablets/30 days depending on pack size)
    Formulation notesDifferent PAXLOVID pack configurations have distinct QLs (11–30 tablets/30 days per formulary lines).
    Provider actionDispense according to pack QL and seek authorization if exceeding limits.
    SUNLENCA / lenacapavir pack examples
    SUNLENCA / lenacapavir packsQL: 4–5 tablets/365 days for therapy packs; LA and SP indicated
    Annual pack limitsCounts for lenacapavir therapy packs are expressed per 365 days in the formulary.
    Specialty routingLA and SP designations imply specialty pharmacy handling.
    PREVYMIS pellet pack QL example
    PREVYMIS pellet packQL: 800 packets/365 days (pellet pack example)
    Long-term QLsSome prophylactic or transplant antivirals use annual packet counts rather than monthly limits.
    Formulation-notePellet packs have packet-based QLs listed explicitly in formulary.
    abiraterone acetate QL examples
    Abiraterone acetateQL: 120 tablets/30 days for 250 mg; 60 tablets/30 days for 500 mg (PA/SP indicated)
    Therapeutic classAndrogen biosynthesis inhibitor used in oncology; QLs differ by strength.
    Provider actionObtain PA and dispense within the QL for the listed strength.
    ALECENSA QL example
    ALECENSA (alectinib)QL: 240 capsules/30 days; LA/PA/SP indicated
    AdministrationOral targeted therapy with high-count capsule QL typical for chronic dosing.
    Utilization controlsOften paired with PA and specialty management.
    dasatinib 20 mg QL example
    Dasatinib 20 mgQL: 90 tablets/30 days (PA and SP indicated)
    Other dasatinib strengthsLower QL (30 tablets/30 days) applied for other strengths per formulary lines.
    Specialty designationSP noted on dasatinib entries; PA required.
    ensartinib cap 25 mg QL example
    Ensartinib cap 25 mgQL: 30 capsules/30 days (PA, SP indicated)
    Higher-strength capsENSACOVE 100 mg listed with QL 60 capsules/30 days.
    Provider notePA and SP applied to ensartinib formulations.
    LENVIMA therapy pack QL example
    LENVIMA therapy packQL: 30 capsules/30 days for 10 mg daily dose (PA/QL/SP indicated)
    Higher-dose packsOther LENVIMA pack configurations have larger QLs (e.g., 90 capsules/30 days).
    Site/ProgramOften LA/PA/SP accompany these oncology therapy packs.
    PIQRAY 250 mg QL example
    PIQRAY 250 mgQL: 56 tablets/28 days (PA, SP indicated)
    PIQRAY 300 mgQL: 56 tablets/28 days (PA, SP indicated)
    PackagingPack-based tablet counts used to reflect daily dosing regimens.
    PIQRAY 300 mg QL example
    PIQRAY 300 mgQL: 56 tablets/28 days (PA, SP indicated)
    Dose packTwo 150 mg tablets per day packaging reflected in the 56-tablet QL.
    AuthorizationPA required per formulary.
    POMALYST QL example
    POMALYSTQL: 21 capsules/28 days (LA, PA, SP indicated)
    IndicationUsed in multiple myeloma; restricted pack/28‑day QL applies.
    Provider actionPA and specialty routing required per formulary.
    REVUFORJ QL example
    REVUFORJ 110 mgQL: 120 tablets/30 days (LA, PA, SP indicated)
    Multiple strengthsOther strengths list differing QLs (e.g., 240, 60 tablets/30 days per strength).
    Site/programOften accompanied by LA and SP flags for distribution.
    ROZLYTREK pellet pack QL example
    ROZLYTREK pellet pack 50 mgQL: 336 packets/28 days (LA, PA, SP indicated)
    Capsule variantsCapsule forms have lower QLs (e.g., 30 or 90 capsules/30 days).
    DistributionPA and specialty handling specified on formulary lines.
    VENCLEXTA STARTING PACK QL example
    VENCLEXTA STARTING PACKQL: 1 pack/180 days (LA, PA, SP indicated)
    Starter pack rationaleStarter/induction packs have longer period QLs to control initial dosing supplies.
    AuthorizationPA/LA often required for starter packs.
    DEXAMETHASONE elixir/solution entries (varies)
    DEXAMETHASONE elixir/solutionFormulation entries vary; some list no QL in the excerpt while others specify limits per product.
    Tablets vs solutionsTablets have standard tablet QLs; liquid/solution forms may have mL-based QLs when specified.
    Provider noteCheck the specific line-item for dexamethasone formulation and any QL or PA requirements.
    ALORA patch QL example
    ALORA patchQL: 8 patches/28 days (estradiol transdermal patch example)
    Patch QLsTransdermal patches typically have patch-count QLs per 28 or 30 days.
    Provider actionDispense within patch QLs unless prior authorization allows override.
    MYFEMBREE QL example
    MYFEMBREEQL: 30 tablets/30 days; PA required
    ORIAHNNQL: 1 box/28 days; PA required
    Contraceptive ACA examplesSome contraceptives are ACA‑annotated and may have ACA-related coverage considerations.
    ANNOVERA QL / ACA example
    ANNOVERAMarked ACA on formulary (contraceptive ring) — ACA preventive coverage annotation
    Other contraceptivesMultiple contraceptive brands/formulations listed with ACA or QL annotations as applicable.
    Provider noteCheck ACA designation for preventive coverage implications.
    MYFEMBREE QL example (duplicate)
    MYFEMBREE (duplicate)QL: 30 tablets/30 days; PA indicated
    ContextListed among contraceptive and gynecologic therapy entries with PA/QL flags.
    AuthorizationPA required per formulary line.
    ORIAHNN QL example
    ORIAHNNQL: 1 box/28 days; PA indicated
    PackagingPack-based QL consistent with monthly dispensing cycle.
    Provider actionSubmit PA when required for coverage of ORIAHNN.
    MOUNJARO QL examples (4 pens)
    MOUNJARO (selected strengths)QL: 4 pens (period depending on presentation); PA/QL indicated
    MOUNJARO (other strengths)Also listed with 4 pens per period in formulary entries (presentation-dependent)
    Provider noteCheck exact presentation on formulary line for the applicable QL and PA.
    MOUNJARO other strengths QL
    MOUNJARO other strengthsQL: 4 pens (presentation-dependent); PA noted
    Dispensing intervalPen-count QLs often reference 28 or 30 day periods depending on product.
    Specialty designationMany GLP‑1 agonists flagged PA/SP in the formulary.
    OZEMPIC QL example
    OZEMPICQL: 1 pen or 3 pens depending on presentation; PA indicated
    Presentation-dependent QLSome presentations allow 1 pen per period while others permit 3 pens per period — check formulary line.
    Provider notePA and QL apply to semaglutide pen presentations.
    TRULICITY QL example
    TRULICITYQL: 4 pens/28 days for some strengths; 2 pens/28 days for higher strengths; PA may apply
    Strength‑dependent limitsDifferent pen-count QLs reflect varied dosing schedules by strength.
    Provider actionRefer to the specific strength entry for the applicable QL and PA requirements.
    Multiple insulin products QL example (100 mls)
    Multiple insulin productsQL: 100 mls/30 days commonly applied across many insulin pen/cartridge presentations
    ExamplesFIASP, HUMALOG, NOVOLOG, HUMULIN, NOVOLIN entries list QL 100 mls/30 days.
    Dispensing noteLiquid insulin QLs expressed in mLs standardize limits across pen and vial presentations.
    Multiple insulins QL (examples HUMULIN, NOVOLIN, HUMALOG MIX, NOVOLOG MIX)
    HUMULIN / NOVOLIN examplesQL: 100 mls/30 days for multiple regular and NPH insulin formulations
    Pen and vial parityQL applies to both pen-injector and vial presentations as listed.
    Provider actionDispense within the 100 mL monthly limit unless payer authorizes exception.
    GALAFOLD QL example
    GALAFOLDQL: 14 capsules/28 days; LA/PA/SP indicated
    Rare disease therapiesOften have small capsule-count QLs and specialty/lab monitoring requirements.
    Provider notePA and specialty routing apply for GALAFOLD per formulary.
    FOLLISTIM AQ formulations QL examples
    FOLLISTIM AQ cartridgesQL: varies by strength — examples include 15, 8, or 5 cartridges per 30 days depending on strength
    Dosing-based QLsCartridge counts change with strength; check the specific cartridge strength entry.
    Specialty handlingPA/LA/SP commonly accompany these fertility injectables.
    IMCIVREE QL example
    IMCIVREE (setmelanotide)QL: 10 vials/30 days; LA/PA/SP indicated
    DistributionListed with LA and PA reflecting restricted specialty supply.
    Provider actionPA and specialty documentation required for coverage.
    PREGNYL 10000 unit QL example
    PREGNYL 10000 unitQL: 2 vials/30 days; PA and SP indicated
    Reproductive therapy QLsHigh-unit injectable products use vial-count QLs per month.
    Provider notePA and specialty handling apply per formulary entry.
    TYMLOS QL example
    TYMLOS (abaloparatide)QL: 1 pen/30 days; LA/PA/SP indicated
    Pen-based QLsOsteoporosis biologic pens often limited to 1 pen per month.
    Provider actionPA and specialty routing are typical for these products.
    VOXZOGO QL example
    VOXZOGO (vosoritide)QL: 30 vials/30 days; LA/PA/SP indicated
    Pediatric biologic vial countsHigh vial-count monthly QLs reflect dosing and supply requirements.
    Specialty designationLA/PA/SP noted for distribution control.
    YORVIPATH QL example
    YORVIPATHQL: 2 pens/28 days; LA/PA/SP indicated
    Pen-count limitsPen-based biologic therapies commonly limited by pen count per month.
    Provider notePA and specialty routing typically required for coverage.

    Site of Care and Specialty Routing

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Biosimilars and Related Controls

    Note
  1. Documentation for restricted products: The plan may require manufacturer paperwork, prior therapy failure documentation, or specialty pharmacy enrollment to authorize coverage.